A5025506806- Lung Cancer Treatments and Mutations
- Lymphoma Diagnosis and Treatment
- Cholesterol and Lipid Metabolism
- Cancer, Lipids, and Metabolism
- Lipid metabolism and biosynthesis
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- MicroRNA in disease regulation
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Research Studies
- Helicobacter pylori-related gastroenterology studies
- Cancer-related gene regulation
- Chronic Myeloid Leukemia Treatments
- Inflammasome and immune disorders
- Cancer Genomics and Diagnostics
- interferon and immune responses
- Sarcoma Diagnosis and Treatment
- Gout, Hyperuricemia, Uric Acid
- CNS Lymphoma Diagnosis and Treatment
- Liver physiology and pathology
- Colorectal Cancer Treatments and Studies
- Metastasis and carcinoma case studies
- Cardiovascular Function and Risk Factors
Peking University
2024
Putian University
2024
Harbin Medical University
2024
First Affiliated Hospital of Fujian Medical University
2024
Fujian Medical University
2024
Peking University People's Hospital
2024
Sun Yat-sen University
2012-2023
Sun Yat-sen University Cancer Center
2012-2023
Cholesterol is often enriched in tumor microenvironment (TME); however, its impact on disease progression varies different tissues and cells. Monocytes/macrophages (Mφ) are major components regulators of the TME play pivotal roles therapeutic responses. We aimed to investigate profile, effects, regulatory mechanisms Mφ cholesterol metabolism context human hepatocellular carcinoma (HCC). Here, we found that patients with high serum levels had shorter survival times lower response rates...
Abstract Lung cancer is a leading cause of cancer‐related deaths worldwide. Recent studies have identified pyroptosis, type programmed cell death, as critical process in the development and progression lung cancer. In this study, we investigated effect EEBR, new compound synthesized by our team, on pyroptosis non‐small cells (NSCLC) underlying molecular mechanisms. Our results demonstrated that EEBR significantly reduced proliferation metastasis NSCLC vitro. Moreover, EEBR‐induced cells,...
Introduction: Amdizalisib (HMPL-689) is an oral, potent and highly selective small molecule phosphoinositide 3-kinase-delta inhibitor, which showed tolerable safety profile promising clinical activity in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma, particularly for follicular lymphoma (FL) pts (2021 ESMO). Here, the updates from this phase 1b study to present all at recommended 2 dose efficacy 4 cohorts will be reported. Methods: Six were enrolled study, including FL,...
Based on Computed Tomography (CT) tomography images of the human heart, a 3D reconstruction and wall optimization heart was performed by using Mimics to model motion left ventricular overflow wall. The non Newtonian blood flow in ventricle numerically simulated dynamic mesh technique based User Defined Functions UDF programming motion. When is diastolic, internal pressure gradually increases, structure approximates physiological pattern, rate at mitral orifice first increases then decreases,...
<h3>Background:</h3> While glucocorticoids and immunosuppressive therapies are key treatment approaches in SLE, these may contribute to damage accrual. Given the long horizon of tapering therapy stable SLE is often considered, but whether this approach impacts accrual unknown. <h3>Objectives:</h3> We aim compare time new among patients whose and/or were tapered after achieving target, versus those was continued on same doses. <h3>Methods:</h3> followed (ACR/SLICC criteria) from 13...
<p>Supplementary Figure S1-S5 and Table S1-S3</p>
<p>Supplementary Figure S1-S5 and Table S1-S3</p>
Diffuse large B-cell lymphoma (DLBCL) is one of the most common yet aggressive types and remains incurable in 40% patients. Herein, we profiled transcriptomes 94,324 cells from 17 DLBCLs 3 control samples using single-cell RNA-sequencing technology, creating a comprehensive map for tumor infiltrating immune DLBCL. High degrees inter- intratumor heterogeneity were revealed, identified 73 gene expression programs expressed malignant B cells. We further characterized 8 nonmalignant subclusters...
Background: Linperlisib is an oral highly selective small molecule inhibitor of PI3Kδ that well-tolerated with a favorable PK profile in patients lymphomas and advanced solid tumors. This phase Ib study evaluating the efficacy safety relapsed or refractory peripheral T-cell lymphoma (PTCL), aggressive malignancy few treatment options for patients. Methods: Eligible PTCL had received at least 1 prior systemic therapy were administered 80mg orally once daily (RP2D) 28 day cycles until disease...
Introduction: Inhibition of histone methyltransferase EZH2 represents a rational therapeutic strategy for lymphomas. SHR2554 is an oral small-molecule inhibitor exhibiting potent selectivity EZH2. The multicenter, 2-part, phase 1 study was initiated to assess in patients (pts) with r/r lymphomas (NCT03603951). In part I, 350 mg BID established as the recommended 2 dose (RP2D) based on findings dose-escalation and expansion phases; subsequently, pts selected lymphoma subtypes were recruited...
Background: Patients (pts) with relapsed/refractory (R/R) DLBCL and iNHL who are ineligible for, or relapse after, high-dose chemotherapy (HDC)/autologous stem cell transplantation (ASCT) have a poor prognosis limited treatment options. Selinexor, selective inhibitor of nuclear export has been approved by the US Food Drug Administration for R/R DLBCL. We hereby present preliminary results phase I/II study (NCT05265975) evaluating safety tolerability selinexor in combination R2 iNHL. Methods:...
Introduction: Linperlisib, a PI3Kδ inhibitor, has shown clinically efficacy and manageable safety profile as third- or further-line treatment in patients with R/R FL from multicenter phase 2 trial (NCT04370405). We aimed to perform subgroup analysis evaluate the impact of POD24, well-established indicator poor survival, on linperlisib. Methods: This study was conducted at 25 sites China between April 2019 September 2020. Linperlisib 80 mg given orally once daily until disease progression,...
Background: Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous lymphoma, and it more difficult to treat for high risk group. The 3-year overall survival (OS) rate of patients with IPI score 0–1, 2, 3, 4–5 were 91%, 81%, 65% 59%, respectively. efficacy was limited even after intensive chemotherapy under R-CODOX-M/R-IVAC (ORR 74.5%; CR 47.3%). GCB subtype has better prognosis, but 20% still relapsed R-CHOP [6], no benefit achieved by modifying regimen new agent like pola-R-CHP....
<p>Supplementary Figure S1-S5 and Table S1-S3</p>
<p>Supplementary Figure S1-S5 and Table S1-S3</p>
<div>Abstract<p>Cholesterol is often enriched in tumor microenvironment (TME); however, its impact on disease progression varies different tissues and cells. Monocytes/macrophages (Mφ) are major components regulators of the TME play pivotal roles therapeutic responses. We aimed to investigate profile, effects, regulatory mechanisms Mφ cholesterol metabolism context human hepatocellular carcinoma (HCC). Here, we found that patients with high serum levels had shorter survival times...
<div>Abstract<p>Cholesterol is often enriched in tumor microenvironment (TME); however, its impact on disease progression varies different tissues and cells. Monocytes/macrophages (Mφ) are major components regulators of the TME play pivotal roles therapeutic responses. We aimed to investigate profile, effects, regulatory mechanisms Mφ cholesterol metabolism context human hepatocellular carcinoma (HCC). Here, we found that patients with high serum levels had shorter survival times...